Ollin Biosciences, Inc. has released positive topline data from its Phase 1b JADE trial evaluating OLN324, a next-generation VEGF/Ang2 bispecific antibody, in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The study showed that OLN324 outperformed faricimab (Genentech’s Vabysmo) in anatomic outcomes for DME and achieved comparable results in wAMD, with no new safety concerns. The U.S.-based biotech firm now plans to move the candidate into global Phase 3 trials in 2026

Why this dual-pathway strategy could redefine retinal disease treatment hierarchy

What makes OLN324 more than just a me-too antibody is its structural and mechanistic differentiation. The molecule delivers up to 60-fold higher anti-Ang2 potency than faricimab and is delivered in a smaller protein format at a higher molar dose. While these features may sound incremental on paper, their biological impact was made evident in the trial’s data: significantly faster and more pronounced retinal drying in DME patients, with a ~75% greater reduction in central subfield thickness (CST) at Week 1 and ~50% at Week 12 compared to faricimab.

This anatomic superiority is clinically relevant in DME, where early and complete resolution of fluid correlates with better long-term visual outcomes. Notably, nearly 90% of patients receiving OLN324 4 mg achieved a dry retina at 12 weeks (CST <325 μm) versus 57% for faricimab. Although visual acuity gains were numerically higher with OLN324, both treatment arms showed comparable mean BCVA improvements by Week 12, aligning with prior evidence that anatomical response often precedes or exceeds functional improvement windows in retinal disease.

Clinicians tracking the field suggest this early drying response could lead to extended treatment intervals and improved real-world compliance, two critical bottlenecks in current anti-VEGF practice. Faricimab had previously set the bar with its dual VEGF-A/Ang2 mechanism and eight- to 16-week dosing flexibility. If OLN324 can replicate its efficacy with even fewer injections, it could expand market share within a therapeutic landscape already facing injection fatigue and treatment burden.

What the JADE trial reveals about comparative benchmarks and trial design

The JADE study was relatively small and short in duration, with 160 patients randomized across three arms—OLN324 2 mg, OLN324 4 mg, and faricimab 6 mg—and primary efficacy assessed at Week 12. Despite the early-stage nature of the data, JADE was notable for directly using faricimab as an active comparator in a randomized setting. That is a strategic move in a space where superiority claims are often diluted by indirect comparisons or placebo-controlled designs.

By selecting faricimab—the most recent market entrant and the only current dual-pathway competitor—as its benchmark, Ollin is making a direct play for first-line positioning. Most other development programs, including high-dose aflibercept (Eylea HD) and biosimilar entrants, have chosen to incrementally build around existing VEGF inhibition. In contrast, OLN324’s JADE data suggests a bold attempt to surpass not just historical standards but the most advanced competitor currently available.

Regulatory watchers believe this comparative trial design may also give OLN324 an advantage in future submissions, particularly in markets such as the United States and Europe, where active-comparator data is increasingly valued for demonstrating clinical benefit over existing options. If replicated in Phase 3 with longer follow-up and functional endpoints, OLN324 may be well-positioned to justify reimbursement at premium pricing tiers.

What this means for Innovent, Regeneron, and the evolving anti-VEGF landscape

OLN324 is being co-developed by Ollin Biosciences and Innovent Biologics (HKEX: 01801) under the internal code IBI324. For Innovent, a China-based pharmaceutical company known for its immuno-oncology and biosimilar programs, OLN324 represents a potential global first-in-class ophthalmology asset—an area where few Chinese firms have historically succeeded outside domestic markets.

For Genentech and Regeneron, the stakes are different. Genentech’s faricimab was only recently launched as Vabysmo in key markets, and while initial uptake has been strong, any erosion from next-generation bispecifics could pressure pricing and rebate structures. Meanwhile, Regeneron’s high-dose Eylea formulation (8 mg) has sought to defend its market position through dosing convenience and durability, but offers no meaningful advancement in target engagement.

Analysts tracking retinal therapeutics suggest that OLN324 could be the first asset to demonstrate true biologic differentiation since the introduction of anti-VEGF agents nearly two decades ago. If Ollin’s Phase 3 program sustains this lead, OLN324 could fracture a duopoly that has historically been dominated by VEGF-A monotherapy—and more recently, VEGF/Ang2 combinations that have not fully realized their potential.

What risks remain before OLN324 can challenge entrenched standards of care

Despite the compelling anatomic results, several critical questions remain unanswered. First, the translation from retinal drying to long-term visual acuity improvements has not yet been proven. While the Week 12 BCVA results were directionally favorable, the study was not powered to detect statistical differences in vision, and there is no indication that these trends will be durable through extended follow-up.

Second, the durability of OLN324’s effects—and whether it can support extended treatment intervals equivalent or superior to faricimab’s 16-week dosing—has not yet been tested. For payers and providers, reducing the injection burden is as critical as improving outcomes, especially in real-world DME and wAMD patients who often struggle with treatment adherence.

Third, safety remains a watchpoint despite the clean profile so far. The JADE study reported no intraocular inflammation with OLN324 and one case in the faricimab arm. While this supports a favorable initial safety signal, the sample size and follow-up duration are insufficient to detect rarer adverse events, including retinal vasculitis, which has historically disrupted the development of similar high-potency biologics.

Finally, manufacturing, scalability, and device delivery are unaddressed in the current announcement. A higher molar dose and smaller format antibody may bring benefits in efficacy but could pose formulation or device compatibility challenges in scale-up. Industry observers note that these technical hurdles often surface only in Phase 3 or during regulatory submissions.

What the planned Phase 3 program and investor signals suggest

Ollin’s announcement that it will initiate global Phase 3 studies in both DME and wAMD in 2026 signals confidence in the asset’s translatability. The company has also confirmed upcoming presentations at the J.P. Morgan Healthcare Conference and the Angiogenesis, Exudation, and Degeneration symposium in early 2026—two major platforms likely to influence both investor sentiment and clinician interest.

If Ollin can sustain investor confidence and operational execution through Phase 3, OLN324 may emerge not just as a strong commercial candidate but as a case study in how small, clinical-stage biotechs can challenge category leaders through focused mechanistic innovation. For payers, providers, and patients, the emergence of a clearly superior bispecific agent would represent a long-awaited inflection point in the management of retinal vascular disease.

  anti-VEGF, bispecific antibody, diabetic macular edema, faricimab, Innovent Biologics, Ollin Biosciences, OLN324, retinal therapeutics, wet AMD